Clinical reasoning AI
35 – 33Isabel DDx Companion by 2
| Dimension | Isabel DDx Companion | OpenEvidence | Gap |
|---|---|---|---|
| Differential qualityWhether the tool produces a ranked differential with explicit rationale and discriminating features, and whether it flags red flags and can-not-miss diagnoses rather than only the likely answer. | 9 | 6 | +3 |
| Reasoning transparencyWhether the reasoning path is inspectable and auditable end to end, so a clinician can find the step they disagree with instead of accepting or rejecting the whole output. | 6 | 3 | +3 |
| Evidence & citationsWhether reasoning steps are tied to identifiable peer-reviewed sources or guidelines, and whether those citations are checked against the claim they support. | 7 | 9 | -2 |
| Workflow integrationWhether reasoning happens inside real clinical work — from an encounter, a chart or a note — or requires re-entering the case into a separate interface. | 6 | 7 | -1 |
| Access & eligibilityPublished pricing, free tier, credential gating, regional availability and language coverage. | 7 | 8 | -1 |
Isabel DDx Companion
- Best for
- Clinicians who want a dedicated, deterministic differential-diagnosis safety check built from age, sex, travel history and clinical findings, backed by more than two decades of published diagnostic-sensitivity studies and newly added LLM Diagnosis Compare tables on Premium.
- Limitation
- Requires manual feature entry or copy-paste, returns long lists averaging 30 to 38 possibilities without an explicit step-by-step reasoning trace, and its LLM comparison tools on the $199 Premium plan run on desktop in English only.
- Price
- 30-day free trial; $149/year Standard; $199/year Premium ($49/year student)
OpenEvidence
- Best for
- Verified US clinicians who want to prompt a case question and receive a fast synthesis cited to licensed medical journals including NEJM and JAMA.
- Limitation
- Built for literature question answering rather than structured differential generation, exposes no reasoning trace, requires a US NPI number, and withdrew from the EU and UK in April 2026.
- Price
- Free, funded by pharmaceutical advertising
